Cadrenal Therapeutics (CVKD) Other Non-Current Liabilities (2022 - 2023)
Cadrenal Therapeutics (CVKD) posted Other Non-Current Liabilities of $4.4 million for Q4 2023, little changed sequentially from $4.4 million in Q4 2022, and little changed YoY from $4.4 million in Q4 2022.
Cadrenal Therapeutics (CVKD) Other Non-Current Liabilities (2022 - 2023) Analysis & Trends
Cadrenal Therapeutics has reported Other Non-Current Liabilities for 2 years, with the latest figure at $4.4 million in Q4 2023.
- Quarterly Other Non-Current Liabilities changed 0.0% year-over-year to $4.4 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $4.4 million (changed 0.0% YoY) and the FY2023 annual result came in at $4.4 million, changed 0.0% from the prior year.
- Other Non-Current Liabilities steadied at $4.4 million in Q4 2023 per CVKD's latest filing, from $4.4 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $4.4 million in Q4 2022 and troughed at $4.4 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cadrenal Therapeutics | 4.59 Mn | 2.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 4.38 Mn |
| Dec 31, 2022 | 4.38 Mn |